Literature DB >> 8694295

Large-dose intrathecal morphine for coronary artery bypass grafting.

M A Chaney1, K R Smith, J C Barclay, S Slogoff.   

Abstract

Aggressive control of pain during the immediate postoperative period after cardiac surgery, associated with decreased blood catecholamine levels, may decrease morbidity and mortality. This study investigated the use of large-dose intrathecal morphine for cardiac surgery and its effect on postoperative analgesic requirements and blood catecholamine levels. Patients were randomized to receive either 4.0 mg of intrathecal morphine (Group MS) or intrathecal saline placebo (Group NS). Perioperative care was standardized and included postoperative patient-controlled analgesia. Arterial blood samples were obtained perioperatively to ascertain catecholamine levels. Patients in Group MS required significantly less postoperative intravenous morphine than patients in Group NS. Although perioperative norepinephrine and epinephrine levels in Group MS patients tended to be lower than Group NS patients, the differences were not statistically significant. In conclusion, large-dose intrathecal morphine initiates reliable postoperative analgesia but does not reliably attenuate the stress response during and after cardiac surgery.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8694295     DOI: 10.1097/00000539-199608000-00003

Source DB:  PubMed          Journal:  Anesth Analg        ISSN: 0003-2999            Impact factor:   5.108


  2 in total

Review 1.  Use of nerve block techniques for postoperative analgesia.

Authors:  Per H Rosenberg
Journal:  J Anesth       Date:  1997-12       Impact factor: 2.078

2.  Intrathecal morphine plus general anesthesia in cardiac surgery: effects on pulmonary function, postoperative analgesia, and plasma morphine concentration.

Authors:  Luciana Moraes dos Santos; Verônica Cavani Jorge Santos; Silvia Regina Cavani Jorge Santos; Luiz Marcelo Sá Malbouisson; Maria José Carvalho Carmona
Journal:  Clinics (Sao Paulo)       Date:  2009       Impact factor: 2.365

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.